Fennec Pharmaceuticals Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023
Full-year 2023 net revenues are expected to be approximately $20.7 million to $21.2 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.21 USD | +0.55% | -1.39% | -17.91% |
1st Jan change | Capi. | |
---|---|---|
-17.91% | 250M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |